October 23, 2019
GSK gets FDA approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer
Expanded indication allows for treatment of women whose advanced ovarian cancer is associated with homologous recombination deficiency (HRD) Zejula is…
